Advocacy for aHUS and “aHUSs”
When it comes to advocacy why say there is aHUS and there is also aHUSs? The rare disease aHUS is described…
When it comes to advocacy why say there is aHUS and there is also aHUSs? The rare disease aHUS is described…
Imagine atypical haemolytic uraemic syndrome or aHUS on a well know quiz show, say Mastermind. How would it look?--- The Mastermind…
A PDA or patient decision aid is becoming an important part of the increasing shared decision making by patients and doctors.…
A few days ago an article appeared in The Lancet which claims to be the largest real world analysis of complement…
Recently I wrote an article about a clinical study which is an Ravulizumab pregnancy registry in the USA. Then tried to…
After years of waiting, eculizumab Soliris(R) has been approved by India’s Central Drugs Standard Control Organisation (CDSCO) as an approved drug…
In 2023 a group from the aHUS community met with the FDA to talk to them about living with aHUS and…
Complement inhibition treatment discontinuation is a topic that Global Action has led on in the aHUS patient advocacy world for several…
Recently a novel article about complement inhibitor treatment discontinuation was published. Novel because of the research method used to produce its…